Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 8/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.56 |
| ▸ | MAPT | P10636 | 4/20 | 0.56 |
| ▸ | GAA | P10253 | 3/20 | 0.56 |
| ▸ | BLM | P54132 | 2/20 | 0.56 |
| ▸ | POLB | P06746 | 2/20 | 0.56 |
| ▸ | LMNA | P02545 | 2/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.56 |
| ▸ | NSD2 | O96028 | 1/20 | 0.56 |
| ▸ | ALPL | P05186 | 1/20 | 0.56 |
| ▸ | ALPI | P09923 | 1/20 | 0.56 |
| ▸ | ALPG | P10696 | 1/20 | 0.56 |
| ▸ | APEX1 | P27695 | 1/20 | 0.56 |
| ▸ | HTT | P42858 | 1/20 | 0.56 |
| ▸ | RECQL | P46063 | 1/20 | 0.56 |
| ▸ | CASP6 | P55212 | 1/20 | 0.56 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.56 |
| ▸ | TPMT | P51580 | 1/20 | 0.52 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.47 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31148957 | 0.95 | KDM4E (0.56) | KDM4EALDH1A1MAPTGAABLM | |
| SCHEMBL838851 | 0.87 | KDM4E (0.48) | KDM4EALDH1A1MAPTGAABLM | |
| SCHEMBL1893743 | 0.82 | KDM4E (0.68) | KDM4EALDH1A1MAPTGAABLM | |
| SCHEMBL12355763 | 0.81 | KDM4E (0.56) | KDM4EALDH1A1MAPTGAABLM | |
| SCHEMBL8432669 | 0.79 | POLB (0.62) | KDM4EMAPTGAAPOLBLMNA | |
| SCHEMBL661545 | 0.79 | HDAC8 (0.69) | KDM4EALDH1A1MAPTPOLBHDAC8 | |
| SCHEMBL15872015 | 0.78 | HDAC6 (0.63) | GAAPOLBTPMTHDAC3HDAC4 | |
| SCHEMBL1003295 | 0.78 | TPMT (0.54) | KDM4EALDH1A1MAPTGAAPOLB | |
| SCHEMBL7787094 | 0.78 | KDM4E (0.58) | KDM4EALDH1A1MAPTGAABLM | |
| SCHEMBL11341058 | 0.78 | KDM4E (0.58) | KDM4EALDH1A1MAPTGAABLM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 74 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-3698699-B2 | — | — | 2005-09-21 | — | — | JP | claimed |
| CN-1161325-C | Diacyl hydrazide compounds as insecticide, intermediate for preparing said compounds and their preparing process | 江苏省农药研究所 | 2004-08-11 | — | — | CN | claimed |
| US-20040106724-A1 | Natural rubber produced from latex and composition comprising the same | BRIDGESTONE CORPORATION (JP) | 2004-06-03 | — | — | US | claimed |
| JP-2004514009-A | — | — | 2004-05-13 | — | — | JP | claimed |
| EP-1332161-A2 | DRYING PROCESSES FOR NATURAL RUBBER, STABILIZED NR COMPOSITIONS | Bridgestone Corporation (JP) | 2003-08-06 | — | — | EP | claimed |
| US-6531527-B2 | Liquid dilution after coagulation | BRIDGESTONE CORPORATION (JP) | 2003-03-11 | — | — | US | claimed |
| WO-2002038667-A2 | NATURAL RUBBER PRODUCED FROM LATEX AND COMPOSITION COMPRISING THE SAME | BRIDGESTONE CORPORATION (JP) | 2002-05-16 | — | — | WO | claimed |
| US-20020035195-A1 | Viscosity-stabilizer-containing natural rubber latex and natural rubber and a production process thereof | BRIDGESTONE CORPORATION | 2002-03-21 | — | — | US | claimed |
| WO-2023161296-A1 | CONJUGATION METHOD INVOLVING A TRANSGLUTAMINASE AT THE FC REGION COMPRISING A TRIMMED N-GLYCAN | ADC THERAPEUTICS SA (CH) | 2023-08-31 | — | — | WO | disclosed |
| US-11634391-B2 | Compounds which are inhibitors of Notum | UCL BUSINESS LTD (GB) | 2023-04-25 | — | — | US | disclosed |
| EP-3843844-A1 | COMPOUNDS | UCL Business Ltd (GB) | 2021-07-07 | — | — | EP | disclosed |
| US-20210171475-A1 | COMPOUNDS | UCL BUSINESS LTD (GB) | 2021-06-10 | — | — | US | disclosed |
| WO-2020043866-A1 | COMPOUNDS | UCL BUSINESS LTD (GB) | 2020-03-05 | — | — | WO | disclosed |
| EP-2906553-B1 | OREXIN RECEPTOR ANTAGONISTS WHICH ARE [ORTHO BI (HETERO )ARYL]-[2-(META BI (HETERO)ARYL)-PYRROLIDIN-1-YL]-METHANONE DERIVATIVES | IDORSIA PHARMACEUTICALS LTD (CH) | 2019-06-26 | — | — | EP | disclosed |
| EP-0636608-A1 | Derivatives of 1-benzenesulfonyl-1,3-dihydro-indol-2-one, their preparation and pharmaceutical compositions containing them | SANOFI (FR) | 1995-02-01 | — | — | EP | disclosed |
| EP-0636609-A1 | 1-Benzyl-1,3-dihydro-indol-2-one derivatives, their preparation, the pharmaceutical compositions containing them | SANOFI (FR) | 1995-02-01 | — | — | EP | disclosed |
| EP-0613924-A1 | Natural rubber treated with viscosity stabilizers and production thereof | BRIDGESTONE CORPORATION (JP) | 1994-09-07 | — | — | EP | disclosed |
| EP-0581939-A1 | N-SULPHONYL-2-OXOINDOLE DERIVATIVES HAVING AFFINITY FOR VASOPRESSIN AND/OR OCYTOCIN RECEPTORS | SANOFI (FR) | 1994-02-09 | — | — | EP | disclosed |
| WO-1993015051-A1 | N-SULPHONYL-2-OXOINDOLE DERIVATIVES HAVING AFFINITY FOR VASOPRESSIN AND/OR OCYTOCIN RECEPTORS | ELF SANOFI (FR) | 1993-08-05 | — | — | WO | disclosed |
| US-4212867-A | FOR AGRICULTURAL USE | PHILAGRO (FR) | 1980-07-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11634391-B2 | Compounds which are inhibitors of Notum | NOTUM, GOT2, GOT1 | KDM4E 3907/4885ALDH1A1 1260/4885MAPT 1431/4885 |
| US-20210171475-A1 | COMPOUNDS | GOT2, GOT1, OAT | KDM4E 4149/4885ALDH1A1 658/4885MAPT 315/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.